688363 华熙生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)5.1868.72815.74514.59713.497
总资产报酬率 ROA (%)4.2206.91011.99711.83512.085
投入资产回报率 ROIC (%)4.9528.25914.67813.97913.390

边际利润分析
销售毛利率 (%)73.92973.32076.99078.06681.408
营业利润率 (%)11.25611.65917.86918.30228.755
息税前利润/营业总收入 (%)11.08311.04217.10117.98228.806
净利润/营业总收入 (%)9.2669.59115.11815.67524.500

收益指标分析
经营活动净收益/利润总额(%)104.35490.87591.27687.82793.194
价值变动净收益/利润总额(%)-1.1370.3981.0363.1504.944
营业外收支净额/利润总额(%)0.102-0.950-0.018-1.7250.244

偿债能力分析
流动比率 (X)2.3612.5582.4472.8456.626
速动比率 (X)1.2031.6291.7412.3385.764
资产负债率 (%)18.81617.55123.02324.00512.223
带息债务/全部投入资本 (%)-0.3070.1733.4782.381-1.451
股东权益/带息债务 (%)-30,870.66655,551.4262,675.7143,924.090-6,794.689
股东权益/负债合计 (%)429.348467.119331.894316.387718.383
利息保障倍数 (X)-60.180-21.787-22.350-1,798.523-1,482.564

营运能力分析
应收账款周转天数 (天)34.12326.53823.92027.97650.866
存货周转天数 (天)327.385254.954230.122196.693290.987